A Bedside Decision Instrument To Elicit a Patient's Preference Concerning Adjuvant Chemotherapy for Breast Cancer
暂无分享,去创建一个
[1] A. Mehrez,et al. The Healthy-years Equivalents , 1991, Medical decision making : an international journal of the Society for Medical Decision Making.
[2] T E Hughes,et al. Patient involvement in health care. A procedural justice viewpoint. , 1991, Medical care.
[3] M. Gent,et al. When is a prognostic factor useful? A guide for the perplexed. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] B E Hillner,et al. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. , 1991, The New England journal of medicine.
[5] V. Shih,et al. Aminoaciduria due to vinyl-GABA administration. , 1990, The New England journal of medicine.
[6] G. Rose. Reflections on the changing times. , 1990, BMJ.
[7] David V. Budescu,et al. Dyadic decisions with numerical and verbal probabilities , 1990 .
[8] G M Clark,et al. How to use prognostic factors in axillary node-negative breast cancer patients. , 1990, Journal of the National Cancer Institute.
[9] S. Wartman,et al. When competent patients make irrational choices. , 1990, The New England journal of medicine.
[10] A Gafni,et al. Evaluating health related quality of life: an indifference curve interpretation for the time trade-off technique. , 1990, Social science & medicine.
[11] L. Siminoff,et al. Effects of outcome framing on treatment decisions in the real world: impact of framing on adjuvant breast cancer decisions. , 1989, Medical decision making : an international journal of the Society for Medical Decision Making.
[12] L. Siminoff,et al. Doctor-patient communication about breast cancer adjuvant therapy. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] C K Osborne,et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. , 1989, The New England journal of medicine.
[14] C. Redmond,et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. , 1989, The New England journal of medicine.
[15] W. McGuire. Adjuvant therapy for node-negative breast cancer. , 1989, The New England journal of medicine.
[16] G. Loomes,et al. The use of QALYs in health care decision making. , 1989, Social science & medicine.
[17] M. Zelen,et al. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. , 1989, The New England journal of medicine.
[18] G. Guyatt,et al. Quality of life in stage II breast cancer: an instrument for clinical trials. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] W. Mackillop,et al. Cancer patients' perceptions of their disease and its treatment. , 1988, British Journal of Cancer.
[20] I. Henderson,et al. Adjuvant systemic therapy for early breast cancer. , 1987, Current problems in cancer.
[21] N F Boyd,et al. Eliciting preferences for alternative drug therapies in oncology: influence of treatment outcome description, elicitation technique and treatment experience on preferences. , 1987, Journal of chronic diseases.
[22] G. Bonadonna,et al. Adjuvant systemic therapy for resectable breast cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] B. Cassileth,et al. Information and participation preferences among cancer patients. , 1980, Annals of internal medicine.